Tao An

Tao An

Auto-generated profile, based on publicly available information

Tao An

School of Pharmaceutical Sciences, Qilu University of Technology (Shandong Academy of Sciences), Jinan, Shandong, 250014, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2022 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
TATao An
Tao An
HYHuanhuan Yin
Huanhuan Yin
YLYanting Lu
Yanting Lu
LFLiu Feng
Liu Feng
Plant-derived sesquiterpene lactones are promising natural sources for the discovery of anti-cancer drugs. As an extensively studied sesquiterpene lactone, the tumor suppression effect of parthenolide (PTL) has been clarified by targeting a number of prominent signaling pathways and key protein regulators in carcinogenesis. Notably, PTL was also the first small molecule reported to eradicate cancer stem cells. Nevertheless, the clinical application of PTL as an antitumor agent remains limited, owing to some disadvantages such as low water solubility and poor bioavailability. Thus, nanomedicine has attracted much interest because of its great potential for transporting poorly soluble drugs to desired body sites. In view of the significant advantages over their free small-molecule counterparts, nanoparticle delivery systems appear to be a potential solution for addressing the delivery of hydrophobic drugs, including PTL. In this review, we summarized the key anticancer mechanisms underlined by PTL as well as engineered PTL nanoparticles synthesized to date. Therefore, PTL nanoformulations could be an alternative strategy to maximize the therapeutic value of PTL. Graphical Abstract:

30 December 2022 in LWT
Verified
Journal Article
Open access
MZMeng Zhang
Meng Zhang
HCHui Chen
Hui Chen
ZFZhenhua Feng
Zhenhua Feng
TATao An
Tao An
FLFeng Liu
Feng Liu

26 June 2019 in World Journal of Clinical Cases
Verified
Journal Article
Open access
SHSen Han
Sen Han
TATao An
Tao An
WLWei-Ping Liu
Wei-Ping Liu
YSYuqin Song
Yuqin Song
JZJun Zhu
Jun Zhu
Cardiovascular side effects occur frequently during anti-cancer treatment, and there is a growing concern that they may lead to premature morbidity and death. A 32-year-old woman was diagnosed with breast cancer. After comprehensive treatment with neoadjuvant chemotherapy, surgery, postoperative adjuvant chemotherapy, postoperative adjuvant radiotherapy, and endocrine therapy, her breast cancer was cured. However, heart failure associated with anti-cancer treatment presented, most probably related to chemotherapy containing anthracycline. After active treatment, her cardiac function returned to normal. Unfortunately, follow-up visits revealed a second primary malignancy, lymphoma. After multiple courses of chemotherapy combined with targeted therapy, her lymphoma acquired complete remission and no cardiotoxicity was observed again. Heart failure related to breast treatment may be reversible. Using alternatives to anthracycline in patients with lymphoma who are at risk of cardiac failure may preserve cardiac function.